Universitas Muhammadiyah Sidoarjo
Login


Indonesian Journal on Health Science and Medicine

 Submit manuscript
Section Articles

Assessment of Serum Omentin-1 in Prostate Cancer: Correlation with Anthropometric and Biochemical Factors

Vol. 3 No. 1 (2026): July:
DOI : https://doi.org/10.21070/ijhsm.v3i1.367
Published : Jan 10, 2026

Ali Miqdad Mohammed (1), Abrar I. Albadr (2), Haider Jaber Sagban (3)

(1) Department of Biochemistry, College of Medicine, University of Basrah, Basrah, Iraq
(2) Lecturer, M.B.Ch.B, FIBMS (Chem. Path.), Department of Biochemistry,College of Medicine, University of Basrah, Basrah, Iraq
(3) Medical Oncologist (Iraqi Board), President of Arab Board for Oncology in Iraq, Iraq
Fulltext View | Download

Abstract:

Background: Omentin-1, a novel adipokine predominantly secreted by visceral adipose tissue, modulates glucose metabolism, inflammation, and carcinogenesis, yet its clinical significance in prostate cancer remains underexplored. Knowledge Gap: While adipokines are implicated in obesity-related malignancies, the specific relationship between serum omentin-1 levels and prostate cancer, particularly regarding body mass index and metabolic parameters, is not fully understood. Aims: This study evaluated serum omentin-1 concentrations in 88 newly diagnosed prostate cancer patients compared to 88 age-matched healthy controls, examining correlations with anthropometric measurements and biochemical markers. Results: Serum omentin-1 levels were significantly elevated in prostate cancer patients, particularly in younger age groups and normal-weight to overweight categories, with negative correlation to BMI (r=−0.3, p<0.01) and positive correlation to PSA (r=0.5, p<0.01); multivariate regression identified omentin-1 as an independent protective factor (OR=0.79, p<0.0001). Novelty: This research establishes omentin-1 as an independent predictor of prostate cancer risk alongside traditional biomarkers. Implications: These findings suggest omentin-1 may serve as a complementary biomarker reflecting metabolic-oncological interactions in prostate cancer risk stratification.
Keywords : Omentin-1, Prostate Cancer, Body Mass Index, Prostate-Specific Antigen, Adipokines
Highlight :



  • Omentin-1 levels negatively correlate with BMI but positively correlate with PSA levels.

  • Elevated omentin-1 particularly evident in younger age groups and normal-weight individuals.

  • Omentin-1 identified as independent protective factor against prostate cancer in regression analysis.

References

X. Escoté, S. Gómez-Zorita, M. López-Yoldi, I. Milton-Laskíbar, A. Fernández-Quintela, J. A. Martínez, M. J. Moreno-Aliaga, and M. P. Portillo, "Role of Omentin, Vaspin, Cardiotrophin-1, TWEAK and NOV/CCN3 in Obesity and Diabetes Development," Int. J. Mol. Sci., vol. 18, no. 8, p. 1770, Aug. 2017, doi: 10.3390/ijms18081770.

P. Dec, A. Poniewierska-Baran, A. Modrzejewski, and A. Pawlik, "The Role of Omentin-1 in Cancers Development and Progression," Cancers, vol. 15, no. 15, p. 3797, Jul. 2023, doi: 10.3390/cancers15153797.

D. Kounatidis, N. G. Vallianou, I. Karampela, E. Grivakou, and M. Dalamaga, "The Intricate Role of Adipokines in Cancer-Related Signaling and the Tumor Microenvironment: Insights for Future Research," Semin. Cancer Biol., vol. 113, pp. 130-150, Aug. 2025, doi: 10.1016/j.semcancer.2025.05.013.

B. Cabia, S. Andrade, M. C. Carreira, F. F. Casanueva, and A. B. Crujeiras, "A Role for Novel Adipose Tissue-Secreted Factors in Obesity-Related Carcinogenesis," Obes. Rev., vol. 17, no. 4, pp. 361-376, Apr. 2016, doi: 10.1111/obr.12377.

K. A. Brown and P. E. Scherer, "Update on Adipose Tissue and Cancer," Endocr. Rev., vol. 44, no. 6, pp. 961-974, Nov. 2023, doi: 10.1210/endrev/bnad015.

A. Borowski and L. Siemińska, "Serum Omentin Levels in Patients With Prostate Cancer and Associations With Sex Steroids and Metabolic Syndrome," J. Clin. Med., vol. 9, no. 4, pp. 1-13, Apr. 2020, doi: 10.3390/jcm9041179.

J. Nuszkiewicz, J. Czuczejko, W. Dróżdż, A. Woźniak, B. Małkowski, and K. Szewczyk-Golec, "Concentration of Selected Adipokines and Factors Regulating Carbohydrate Metabolism in Patients With Head and Neck Cancer in Respect to Their Body Mass Index," Int. J. Mol. Sci., vol. 24, no. 4, p. 3283, Feb. 2023, doi: 10.3390/ijms24043283.

G. Panagiotou, L. Mu, B. Na, K. J. Mukamal, and C. S. Mantzoros, "Circulating Irisin, Omentin-1, and Lipoprotein Subparticles in Adults at Higher Cardiovascular Risk," Metabolism, vol. 63, no. 10, pp. 1265-1271, Oct. 2014, doi: 10.1016/j.metabol.2014.06.001.

J. Menzel, R. Di Giuseppe, R. Biemann, C. Wittenbecher, K. Aleksandrova, T. Pischon, A. Fritsche, H.-U. Häring, H. Boeing, M. B. Schulze, and K. Kuxhaus, "Omentin-1 and Risk of Myocardial Infarction and Stroke: Results From the EPIC-Potsdam Cohort Study," Atherosclerosis, vol. 251, pp. 415-421, Aug. 2016, doi: 10.1016/j.atherosclerosis.2016.06.003.

U. Uyeturk, H. Sarıcı, B. Kın Tekce, M. Eroglu, E. Kemahlı, U. Uyeturk, S. Gucuk Ipek, and E. Akan Akkus, "Serum Omentin Level in Patients With Prostate Cancer," Med. Oncol., vol. 31, no. 4, pp. 1-5, Apr. 2014, doi: 10.1007/s12032-014-0923-0.

K. Aleksandrova, R. di Giuseppe, B. Isermann, R. Biemann, M. Schulze, C. Wittenbecher, H. Boeing, and T. Pischon, "Circulating Omentin as a Novel Biomarker for Colorectal Cancer Risk: Data From the EPIC-Potsdam Cohort Study," Cancer Res., vol. 76, no. 13, pp. 3862-3871, Jul. 2016, doi: 10.1158/0008-5472.CAN-15-3464.

R. Ribeiro, C. Monteiro, A. Azevedo, V. Cunha, A. V. Ramanakumar, A. Fraga, P. Pina, E. Pinheiro, R. Medeiros, and P. Lopes, "Performance of an Adipokine Pathway-Based Multilocus Genetic Risk Score for Prostate Cancer Risk Prediction," PLoS One, vol. 7, no. 6, p. e39236, Jun. 2012, doi: 10.1371/journal.pone.0039236.

N. Salvoza, P. Giraudi, S. Gazzin, D. Bonazza, S. Palmisano, N. de Manzini, and C. Tiribelli, "The Potential Role of Omentin-1 in Obesity-Related Metabolic Dysfunction-Associated Steatotic Liver Disease: Evidence From Translational Studies," J. Transl. Med., vol. 21, no. 1, p. 906, Dec. 2023, doi: 10.1186/s12967-023-04770-3.

L. Zhou, R. Liu, Y. Wang, Q. Huang, Y. Wu, Q. Li, S. Zhang, and H. Zhao, "Altered Circulating Levels of Adipokine Omentin-1 in Patients With Prostate Cancer," Oncotarget, vol. 10, no. 6, pp. 625-632, Jan. 2019, doi: 10.18632/oncotarget.26571.

A. Borowski, L. Siemińska, E. Litwin, M. Nowak, M. Brachet, and E. Malyszko, "Serum Omentin Levels in Patients With Prostate Cancer and Relationship With Sex Hormone-Binding Globulin and Metabolic Syndrome," Adv. Clin. Exp. Med., vol. 29, no. 7, pp. 801-809, Jul. 2020, doi: 10.17219/acem/121010.